Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Holdings Trimmed by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lowered its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 16.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,687 shares of the biotechnology company’s stock after selling 7,209 shares during the period. E Fund Management Co. Ltd.’s holdings in Ironwood Pharmaceuticals were worth $431,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Ironwood Pharmaceuticals by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 14,895,700 shares of the biotechnology company’s stock worth $143,446,000 after acquiring an additional 49,160 shares during the period. Victory Capital Management Inc. increased its stake in Ironwood Pharmaceuticals by 17.9% in the 3rd quarter. Victory Capital Management Inc. now owns 4,406,732 shares of the biotechnology company’s stock valued at $42,437,000 after buying an additional 668,694 shares during the period. Armistice Capital LLC purchased a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth approximately $33,281,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Ironwood Pharmaceuticals by 160.9% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,462,300 shares of the biotechnology company’s stock valued at $23,712,000 after buying an additional 1,518,500 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at $22,903,000.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IRWD. StockNews.com cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Wells Fargo & Company dropped their price objective on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, March 1st. Piper Sandler lifted their target price on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Finally, Craig Hallum started coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They set a “buy” rating and a $21.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.80.

Insider Buying and Selling

In related news, CEO Thomas A. Mccourt sold 177,164 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total value of $2,699,979.36. Following the transaction, the chief executive officer now owns 832,774 shares in the company, valued at approximately $12,691,475.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ironwood Pharmaceuticals news, SVP Andrew Davis sold 9,846 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total value of $150,053.04. Following the transaction, the senior vice president now directly owns 208,324 shares of the company’s stock, valued at approximately $3,174,857.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Thomas A. Mccourt sold 177,164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total value of $2,699,979.36. Following the transaction, the chief executive officer now owns 832,774 shares of the company’s stock, valued at $12,691,475.76. The disclosure for this sale can be found here. In the last three months, insiders sold 273,008 shares of company stock valued at $4,160,642. Company insiders own 13.10% of the company’s stock.

Ironwood Pharmaceuticals Trading Down 17.0 %

Ironwood Pharmaceuticals stock traded down $1.38 during trading hours on Thursday, reaching $6.74. 7,358,206 shares of the company were exchanged, compared to its average volume of 4,219,038. Ironwood Pharmaceuticals, Inc. has a 12 month low of $6.21 and a 12 month high of $15.70. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -1.04 and a beta of 0.57. The stock has a 50-day moving average of $8.40 and a 200 day moving average of $10.58.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.